REGENERON PHARMACEUTICALS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
REGENERON PHARMACEUTICALS INC. - More news...
REGENERON PHARMACEUTICALS INC. - More news...
- Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022
- Regeneron Elects Dr. Craig B. Thompson to Board of Directors
- Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
- Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
- Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
- Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
- Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
- Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
- Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
- Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
- Regeneron Announces Investor Call and Webcast at ESMO 2022
- Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
- Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
- ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
- Regeneron Announces Investor Conference Presentations
- Regeneron Reports Second Quarter 2022 Financial and Operating Results
- Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
- Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation
- Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
- Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022
- Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
- EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
- Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
- FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
- Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
- Regeneron Completes Acquisition of Checkmate Pharmaceuticals
- FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
- Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
